Stocks
Akero Therapeutics, Inc.AKRO
NASDAQHealthcareBiotechnology$54.65+0.00%
Focused on developing treatments for serious metabolic diseases, this biopharmaceutical company is advancing therapies for non-alcoholic steatohepatitis (NASH) and other liver conditions. Its lead candidate, efruxifermin, has shown promise in clinical trials, attracting investor interest in its potential to address unmet medical needs.
Market Cap: $4.5B52W Range: $21.34 – $58.40
Congressional Interest in Akero Therapeutics, Inc. (AKRO)
1 member of Congress has disclosed 1 trade in Akero Therapeutics, Inc. (AKRO), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading AKRO?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-11-08 | Christopher L. Jacobs | buy | $1K – $15K |